Receiving a prostate cancer diagnosis is disorienting, particularly because the condition spans such a wide range — from "watch and wait" to urgent systemic treatment. Where you are on that spectrum determines what you need from your medical aid. This article walks you through the practical steps.
Does My Medical Aid Have to Cover This?
Yes. Prostate cancer is a Prescribed Minimum Benefit (PMB) — your medical aid is legally required to fund diagnosis and treatment. The scheme cannot decline coverage.
What PMB does not guarantee: - Payment of specialist fees at your doctor's full rate (they pay at tariff; you may owe the shortfall) - Funding of novel hormonal agents like abiraterone or enzalutamide without an exceptional-needs authorisation - PSA screening before diagnosis (screening is NOT PMB)
Your First Actions After Diagnosis
1. Register with your scheme's oncology case management. Call the oncology case management line (not the general call centre) and register your diagnosis. This triggers a case manager assignment who coordinates pre-authorisations throughout your treatment journey.
2. Get a written staging workup result. Your urologist should provide Gleason/Grade Group, clinical stage, and PSA value in writing. This document is the foundation of every prior authorisation request and exceptional-needs motivation.
3. Ask your urologist what treatment pathway they recommend. Active surveillance, surgery, radiation, or ADT? Each has a different medical aid cost profile and authorisation pathway.
4. Confirm your oncology sub-limit. Check your plan documents or scheme app. This is the annual rand cap on oncology spend. For active surveillance, this is a lower-priority concern. For systemic treatment, it is critical.
Active Surveillance: What Medical Aids Cover
If your urologist has recommended active surveillance (common for Grade Group 1–2, low-risk disease), your cost profile is modest but ongoing: - PSA tests every 3–6 months (~R200–R600 each; may or may not be covered) - Annual MRI (~R5,000–R10,000 with specialist fees; covered on most plans) - Periodic biopsy (~R8,000–R15,000; generally funded)
Total annual cost: approximately R15,000–R30,000. Most plans handle this without sub-limit pressure.
The key risk with active surveillance is transition to active treatment if the cancer progresses. Monitor your PSA trajectory carefully with your urologist.
Surgical and Radiation Treatment: What to Expect
Radical prostatectomy: Surgery to remove the prostate. Prior authorisation required. Major shortfall risk: the surgeon (urologist), anaesthesiologist, and potentially assistant surgeon all bill above medical aid tariff. Total shortfall on a prostatectomy can range from R20,000 to R60,000 depending on technique and specialist rates.
If your urologist recommends robotic-assisted prostatectomy (da Vinci), confirm with your scheme whether they fund the robotic technique or only the open equivalent. If they fund only open surgery, you fund the robotic premium — which can be R30,000–R50,000.
Radiation therapy (EBRT): Multiple treatment sessions over 4–8 weeks. Each session generates a radiation oncologist professional fee shortfall. Cumulative shortfall over a full radiation course can reach R20,000–R40,000.
Androgen Deprivation Therapy (ADT): PMB-Funded
ADT — typically a monthly or quarterly injection of a GnRH agonist (leuprolide or triptorelin) — is the PMB-minimum treatment standard for locally advanced or metastatic prostate cancer. Your scheme must fund this.
Monthly injection cost: approximately R2,500–R3,000. This is an ongoing cost for as long as ADT continues (which may be 18–36 months for locally advanced disease, or indefinitely for metastatic).
Novel Hormonal Agents: Exceptional-Needs Required
If your disease progresses to metastatic castration-resistant prostate cancer (mCRPC), your urologist or oncologist may recommend abiraterone (Zytiga) or enzalutamide (Xtandi). These are not PMB minimum standard in most SA scheme interpretations — they require an exceptional-needs application.
What this means in practice: - Your specialist submits a detailed clinical motivation with staging, PSA, and previous treatment history. - The scheme's medical advisory reviews and approves or declines. - Approval is not guaranteed, but a well-documented application significantly improves the outcome. - If declined, you have the right to appeal and escalate to the Council for Medical Schemes.
Monthly cost for abiraterone: approximately R10,000–R15,000. For enzalutamide: approximately R18,000–R22,000. These are materials costs only, before specialist consultations.
Plan Selection Questions for Prostate Cancer
| Question | Why It Matters |
|---|---|
| What is my oncology sub-limit? | Determines ceiling for systemic treatment cost |
| Does my plan cover PSA screening? | Active surveillance requires regular PSA monitoring |
| Does my scheme fund robotic prostatectomy? | Cost difference can be R30,000–R50,000 per procedure |
| What is my gap cover OPL? | Surgical and radiation shortfalls can be substantial |
| Can I escalate to a higher-option plan mid-year? | Intra-scheme changes possible without new waiting periods |
The Next Three Months: Checklist
| Action | Priority |
|---|---|
| Register with oncology case management | Immediate |
| Obtain written staging/pathology report | This week |
| Confirm oncology sub-limit on your plan | This week |
| Pre-authorise all planned procedures | Before every appointment |
| Ask urologist about robotic vs open surgery funding | Before surgery booking |
| Check gap cover status and OPL | Within 2 weeks |
Support Resources
CANSA (Cancer Association of South Africa): 0800 22 6622 (toll-free) Support groups, patient navigation, counselling
ProstateSA: www.prostatesa.org Prostate cancer patient support network
Talk to Eldon
Get help understanding your plan options →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).